Navigation

Investiment.io
Financial analysis platform

Pfizer Inc.

PFE • NYSE

$28.91
▲0.02 (0.05%)• REGULAR

Pfizer Inc.

$28.91
▲0.1%
📊Summary📋SEC Filings👥Insider Trading
📄

PFE Q3 2024 Earnings Call

December 18, 2024 at 03:00 PM

Company
PFE
Quarter
Q3 2024
Date
December 18, 2024 at 03:00 PM
Speakers
2
Word Count
~6,469

Transcript Content

Operator
We'll take our first question from Chris Shibutani with Goldman Sachs.
Speaker
I wanted to ask questions about the pipeline, particularly with regard to obesity, where we appreciate the additional insights into what you have in the clinic. Albert, you previously said that you believe that Pfizer could be the number two company on the market with an oral. That would imply that danuglipron is the lead asset there; however, you do have two additional assets that we find intriguing at a GP-1 oral that is in Phase I that is once a day but would clearly be behind. And then now an oral GIP antagonist, which I think is a source of debate. Can you frame what your strategy is, how important it is to be second to market versus perhaps having a differentiated approach with these two assets? Albert Bourla (Chairman): Look, I will ask Mikael to comment because there is a lot of activity going on right now. But my general comment is that, as I have said, if Daniel moves fast based on what we know right now, we should be the second oral into the market, provided that the first one will be successful and the other ones will not come before us. So far, this is what the situation looks like. The market is very, very large. And there is a significant need for oral solutions. We know that. So there is no doubt that if successful, we will have our decent market share of oral. But the important thing is that the obesity market is developing, and we are exploring several other opportunities right now. The two that we have mentioned in the clinic, Mikael can speak a little bit more about both the danuglipron and the other two.
Speaker
Thank you, Albert. As mentioned earlier, we are actively progressing with our danuglipron plan, which features a once-a-day regimen with a modified release system. We believe that a daily modified release could offer unique benefits, and introducing this as a second oral option will strengthen our position in the market. Similarly, we've observed that injectables can be divided into two different products. I don't anticipate significant differences among the various oral options within the GLP-1 class. That's why we are also eager to introduce a GIP antagonist that could improve tolerability and enhance efficacy. We are currently starting Phase II studies based on our advancements. These are our two most advanced initiatives, and we continually seek to expand options as we progress. There are numerous applications for GLP-1s, which is why we are also developing a second once-a-day option.
Speaker
I have a question on your recent data from the fensegrumab program in cachexia. You reported positive Phase II data. Broadly speaking, this program has been previously highlighted as well. For the registrational trial, would a trial that replicates your Phase II in a larger group of patients be sufficient? Or would you need to show outcomes like survival? Also, aside from details of the registrational trial, can you help us understand how big of an opportunity you see for this drug? Albert Bourla (Chairman): Let's start with Mikael discussing the science, and then maybe Andrew can talk about the potential market size.
Speaker
In general, for cancer agents, and this is more in the supportive care space, we're addressing segments of unmet patient needs, which relates to regaining the performance status with better body weight, have higher physical activity, and be able to go through more treatment cycles, which should often translate to better long-term survival. As you know, that is always dependent on how patients cross over to different trials. I do think initial registration will come from similar endpoints as in our Phase II studies, but we clearly aim to translate better patient performance to other outcomes that are more hard endpoints going through more treatment cycles and treatments that, call it, with better cancer outcomes over time. This is something that will be shown in multiple cancer types. So we do think similar to other products that have been heavily used in support of cancer care, this could be a very large opportunity. In addition to that, we are running heart failure studies and looking at a third opportunity, also a large chronic disease. With that, Andrew, some comments on the potential of this molecule?
Speaker
Yes, correct. Building on Mikael’s comments, look, cachexia is a massive unmet medical need. It’s prevalent in 50% to 80% of oncology patients, particularly within pancreatic and non-small cell lung cancer. It’s probably about 20% to 30% in heart failure and COPD. The size of the market really depends on whether it’s viewed as a supportive care therapy, but also, obviously, as Mikael mentioned, whether you have outcome benefits. The size of the market, or particularly the size of this drug, is going to be very much informed by the data that we deliver in the pending Phase II and Phase III trials.
Speaker
I feel like it's still very early in your engagement with some of your shareholders and the new shareholders. So perhaps it might be too premature to ask much further on that. So instead, maybe I'll focus on pipeline briefly. I know you mentioned, Mikael, that the oral GIP antagonist adds better tolerability and more efficacy. It sounded like you were implying it's more incremental to what an oral GLP could do as a stand-alone. Could you just lay that into context? For example, in the four-week Phase I study you ran, did it hit 4% to 5% weight loss? And secondly, the more than 30-valent pneumococcal vaccine that you guys disclosed this morning, does it have more than one carrier protein?
Speaker
Yes. The ability of GIPR to act in concert with GLP-1 has been well documented in a few different peptide settings. We aim to be the first to document this with an oral approach, which could offer a nice differentiation for patients that need more rapid achievement of their treatment objectives. That's what we want to reveal right now. Regarding our new platform for PCV generation 4 and 5, we include a number of technical improvements. We don't want to disclose those today, but we were open to mentioning that our PCV fourth generation, which covers 25 serotypes, has an example of improved serotype 3 based on new technology that moves it far beyond what we believe any other technology has accomplished. Why is that important? Well, serotype 3 covers somewhere between 15% to 30% of diseases in different countries, and improving it can have a bigger impact than adding a number of infrequent serotypes. As we go to the more than 30 valence, it will combine such improvement with many more serotypes.
Speaker
I apologize for being on mute. This is Trung Huynh from UBS. I have two questions. Thank you for your insights regarding the activist investor. You mentioned that you disagree with their views on capital deployment and pointed to the significant shareholder returns of Seagen and BioNTech. Can you explain the difference between your perspective and what the market is thinking regarding BD? Additionally, how do you plan to rebuild confidence in the company so that your expectations align with those of the market? On the topic of your commitment to reducing debt, I appreciate your remarks on this. Is there a willingness to expedite the deleveraging process, perhaps by selling the hospital business or offloading the Helion stake sooner? You have products approaching loss of exclusivity, which might provide some additional flexibility for your balance sheet. I'd like to hear your thoughts on this. Albert Bourla (Chairman): Why don't we start with this one, and then I'll take a little bit the activist question. Dave Denton (CFO): Yes. First, on the deleveraging point, yes, our objective is to deleverage as rapidly as possible. The company has been laser-focused on doing that, given the fact that we've taken out about $4.4 billion in debt year-to-date, and we'll continue to do that. Without speaking directly about any potential BD opportunities here, we are always looking to evaluate the infrastructure that we have and the assets that we currently maintain and understand if there's availability to monetize some of those assets over time to further support our deleveraging activity. So I would say all options are on the table, and we'll continue to evaluate what makes the most sense for us strategically long-term. Albert Bourla (Chairman): As regards our projections compared to the Street projections in business development, let’s start by saying that by far, the two biggest deals, Seagen and BioNTech in terms of revenues, right? In both cases, I think the Street has moved on higher than what we predicted when we made the deal. On the other hand, we’re very stable. If you add onto that Biohaven with NURTEC, which we are on track to exceed for the second quarter, Street expectations, it is covering 80% of the investments that we’ve made, and probably way more in terms of revenues. The most important thing is that those two, Seagen and BioNTech, have brought transformational assets to Pfizer. It’s not just the revenue growth, but we are seeing right now, and we’ll continue seeing all the way towards the end of the decade. But it is also due to mega-blockbuster prospects if technical success is achieved. We are moving into Phase III because we have seen very positive earlier data. So I would say that we truly think that this was well-invested capital that will demonstrate significant value for shareholders. But I also want to make a final comment regarding any discussions with activists. No matter if we agree or disagree on what has happened, the most important thing is what we are doing going forward. Starboard has not presented any specific actions, but they suggested something needs to change. I want to indicate that we are already implementing a lot of changes since the beginning of the year. Over the past ten months, we have implemented changes, including changing our commercial model to separate the U.S. and international business and appointing new leaders who have now delivered three consecutive quarters of revenue growth. We integrated Seagen and created an end-to-end oncology research organization to ensure a successful integration of the company and have retained the vast majority of legacy Seagen colleagues, delivering multiple successful readouts. We announced a plan to reduce OpEx by $4 billion, which we are executing successfully without negatively affecting the top line. We implemented a plan to reduce manufacturing costs by $1.5 billion, which is delivering satisfactory results. We have brought in Andrew Baum, who is knowledgeable in research, to help prioritize our R&D pipeline and future business development. We are advancing the process of selecting a new scientific officer. We have enhanced our Board with two new directors who have deep expertise in corporate governance and shareholder value creation. All these changes reflect our intentional five-point plan that we rolled out in January. We plan to engage with all shareholders, including Starboard, and consider any good ideas that create long-term shareholder value. I don’t think that the statement something needs to change is particularly pragmatic, as it seems to be coming fifteen months late.
Speaker
So I just had two here. The first one, I wanted to ask is how we should think about the big pushes and pulls for sales and EPS in 2025? And when you might give guidance? Could it be as early as this year? And then the second one, just on Seagen, just wondering how the integration is coming along and if you have any updates on some of the metrics, like sales in 2030 for the Seagen deal? Dave Denton (CFO): Regarding 2025, it's really topical because we're in the middle, as you can imagine, building our 2025 financial plan across all of our business lines. To your point, there will be many pushes and pulls as we consider growth for next year for both our core business and our COVID business. It’s our expectation that we will provide guidance for 2025, most likely by the end of this year. So stay tuned, more to come. We will lay out all the pushes and pulls when we give guidance for 2025, providing you a clear understanding of our business and the opportunities to enhance shareholder value longer term.
Speaker
Thank you for the question. We are very pleased with the integration so far. We have retained most colleagues from legacy Seagen, and now have over 1,500 colleagues working at our facilities in Basel, near Seattle. In Q3, global revenue from legacy Seagen reached $854 million, with PADCEV contributing over $400 million. Year-to-date, Seagen delivered $2.3 billion for us, representing a 38% year-over-year increase on a pro forma basis. We are executing well on our portfolio and pipeline. We have begun Phase III studies with dasitamab vedotin for urothelial cancer, which affects up to 40% of bladder cancer. For Sigotatacvedotin, the B6A, we initiated the first Phase III study in non-squamous non-small cell lung cancer, where we observed significant data. We also plan to start a combination of sicotatactedotin and pembrolizumab in the first-line setting for non-small cell lung cancer, having aligned with the FDA on trial design and dosing. Additionally, we are progressing towards starting a Phase III program with the PD-L1 V in combination with pembrolizumab early next year. Overall, we have seen great commercial performance and continue to effectively execute on our pipeline.
Speaker
Thanks so much for the question. Just had a couple of quick ones. Mikael, another one on obesity. I know you've added assets outside of danuglipron, and I appreciate it's early. What does success look like on efficacy, just given the current standards? And strategically, how does Pfizer view orals versus longer-acting injectables when considering the investments Pfizer is making in this category? And then real quick, Albert, on the IRA. It seems here to stay, but when you think about the potential for a new administration, what would Pfizer like to see, obviously beyond closing the gap between orals and biologics on exclusivity?
Speaker
For orals, I think you have a number of advantages. One is, of course, the combined effects with all other drugs that are involved in metabolic disease to achieve lasting outcomes. What you're looking for, I would say, is a 10% to 20% weight loss; the lower range for the first GLP, the upper range where you can see oral combinations edge towards. That's very much similar to what you can see with the peptide, so I can provide a broad range with a lower and an aspirational range—lower for more single agents and those agents that we can aspire to go above 15%. Albert Bourla (Chairman): Thank you, Mikael. Now on IRA. Clearly, IRA overall is negative for innovation and does not promote a spirit that encourages investments, but there are also some good things about it. I wouldn’t like to see the out-of-pocket next year being $167 per month for all your medicines for seniors. That, we want to make sure is maintained. However, the forced price setting and negotiation penalties are things that need to change. It’s not only about IRA; I would mention that 340B right now is one of the biggest issues. It is unethical and is evolving in a way that creates a significant transfer of funds from where it needs to be to some businesses to bolster their profit lines. Therefore, 340B reform is something that I, and the entire pharma industry, have prioritized.
Speaker
Great. Appreciate the questions. Two for me. First, regarding the RSV opportunity. What do you see as the most likely outcome for revaccination frequency and the potential impact on the longer-term market opportunity? The second question is more of a clarification. For your CDK4 inhibitor, you guided to starting the first-line Phase III study early next year. If you can share any detail there on the design, will it be a head-to-head against IBRANCE, or will it be a combination with VFD or a monotherapy type design? Albert Bourla (Chairman): Alexandre, could you speak about the RSV market and how it evolves based on the ACIP recommendations, including revaccination and population factors?
Speaker
Yes, absolutely. Even though it's not material yet, we're making very good progress. On the adult front, we've received BTC recommendations since the beginning of the year in large markets like the U.K., Germany, France, Canada, Australia, and various mid-sized markets with positive recommendations. We are also moving into funding, and we recently won exclusive tenders in the U.K. and Canada. Regarding reimbursement, we secured regional reimbursement in Germany and launched in Germany in mid-October. We are negotiating reimbursements in several large and mid-sized markets. On the pediatric side, we are making good progress as well, with recent positive recommendations in numerous countries, including the U.K., France, and Australia. Additionally, we received approval from the Pan-American Health Organization that covers 40 markets in the Americas, providing ABRYSVO with endorsement within those regions. We see great potential, although it will take time to navigate all these stages, we believe it will yield positive results.
Speaker
ABRYSVO's performance in Q3 is substantial, particularly as we approached this vaccination season with adequate stock in fridges, both in retail and health systems. Administration levels began steadily rising in the quarter, even as we anticipate continued volume into Q4. Our significant improvement in market share and sales reflects the effectiveness of our strategies. Albert Bourla (Chairman): Thank you, everyone, for your attention. It was another good quarter for Pfizer. We are executing on the five points plan presented at the beginning of the year, revealing the underlying operational health of our business, the stabilization of the COVID business, and strong growth from the remaining parts of our business. There is significant performance from new products and consistent delivery on our commitments to shareholders. We look forward to continuing this successful path.
Operator
That concludes today's call. You may disconnect at any time.